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The overall outcome of HIV disease
may depend on the host’s capacity to
maintain dendritic cell (DC) homeostasis
at mucosal sites, where DC populations,
one of the earliest cell types to be exposed
to the virus, present an inherent capacity
to modulate the balance between toler-
ance and protection. DCs may influence
mucosal B cell responses against HIV
through contact and/or production of B
cell growth factors such as B lymphocyte
stimulator (BLyS/BAFF), which in turn
modulate the outcome of CD4[super-
script]+[/superscript] T cell HIV effec-
tors/targets. Recent observations of HIV/
SIV infections in non-pathogenic animal
models and from mucosal vaccination of
nonhuman primates suggest that mainte-
nance of systemic integrity may be
achieved through constraining highly effi-
cient immune responses to mucosal sites.
Do Dendritic Cells Drive B Cell
Dysregulation in the Context of
HIV Disease Progression?
B lymphocyte disorders are important
consequences of HIV infection (reviewed in
[1]) and can persist despite therapy and in
the absence of apparent disease progression
[2–5]. DCs play a pivotal role in regulating
the outcome of B cell development, activa-
tion, and survival. This is mediated mainly
through production of B cell growth factors
such as BLyS/BAFF [6–8]. It is therefore
likely that DC alterations associated with
HIV infection [9] have an effect on the B
cell compartment. Early data supporting
this hypothesis were obtained with HIV-
transgenic mice, which develop a Nef-
dependent AIDS-like disease [10]. In these
animals, myeloid DCs (mDCs) present an
immature phenotype and altered stimula-
tory capacities. They accumulate in the
enlarged splenic marginal zone (MZ), likely
contributing to polyclonal B cell activation
and disruption of tolerance [11,12]. BLyS
over expressing mice also present enlarged
splenic MZ, B cell hyperactivity, and
autoimmunity [13]. This phenotype is also
shared by autoimmune-regulatory (AIRE)-
deficient mice, in which bone marrow–
derived DCs over express BLyS [14,15].
Interestingly, AIRE is involved in regula-
tion of STAT1 signalling, a pathway also
used by HIV-Nef to promote pro-inflam-
matory monocytes in humans [16,17] and
likely over expression of tumour necrosis
factor (TNF)-a by DCs [18]. HIV-gp120
can also mediate B cell activation. Indeed,
the binding of gp120 to mannose C-type
lectin receptors on B cells up-regulates the
class switch recombination (CSR)-inducing
enzyme, activation-induced cytidine deam-
inase,resultinginimmunoglobulin(Ig) class
switch from IgM to IgG and IgA with the
help of BLyS [19]. Furthermore, signalling
through toll-like receptor (TLR)7, which
binds to HIV-ssRNA, up-regulates BLyS
expression in DCs [20]. This, along with
the fact that TLR7 is over expressed in
blood DCs from individuals with primary
HIV infection [21], further suggest that
excessive BLyS production by DCs may be
involved in triggering and driving B cell
dysregulation in the context of HIV.
In recent longitudinal studies involving
individuals with HIV with different rates of
disease progression, we have shown that
mDC levels were reduced in the blood of
rapid and classic progressors, beginning in
the acute phase of infection and persisting
throughout the course of disease despite
successful therapy [22]. This correlated
with increased serum levels of DC-tropic
chemokines, suggesting drainage to periph-
eral sites [23]. Most importantly, HIV
progressors had increased levels of BLyS
expression in the plasma and on the surface
of both mature blood mDCs and
CD11c
+CD14
+CD16
2 monocytic DC-
precursors [2]; the latter have been shown
to be associated with inflammatory condi-
tions [24]. In these subjects, B cell dysre-
gulation was found throughout disease
progression and was accompanied by the
increased frequency of a population pre-
senting features shared by both transitional
immature (TI) and MZ B cells [2]. These
cells express low levels of CD21, suggestive
of a non-resting state, and we have thus
named this population ‘‘precursor/activat-
ed MZ-like’’ B cells. Although human MZ
B cells share many commonproperties with
their rodent counterparts, they are not
restricted to the spleen. MZ-like B cells
re-circulate in humans, and have been
identified in several lymphoid tissues such
as the inner wall of the sub-capsular sinus of
lymph nodes, in the crypt epithelium of
tonsils, and under the dome epithelium of
Peyer’s patches in gut-associated lymphoid
tissues (GALT) [25]. However, the human
MZ is a complex heterogeneous niche, and
therefore further characterization is re-
quired to identify the exact nature of the
‘‘precursor/activated MZ-like’’ B cells.
Nevertheless, we think that these cells
represent a ‘‘first line’’ B cell population
that increases in the context of inflamma-
tory conditions such as in HIV infection.
Indeed, TI B cells have been found to be
elevated [26] and to preferentially give rise
to MZ type B cells under conditions of
lymphopenia associated with pathology
[27]. The fact that TI B cells are hyper-
responsive to BLyS [28] and are increased
in the blood of HIV-infected patients with
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over expression may contribute to in-
creased survival of TI B cells and favoured
selection into a MZ-like first line B cell pool
[30]. Given the location of first line B cells
in lymphoid organs and mucosal-associated
lymphoid tissues (MALT), these cells are
highly influenced by DCs and constitute a
T cell–independent defence against invad-
ing pathogens [31]. Also, given their
frequent auto-reactive and cross-reactive
repertoires and their relative hyperactivity,
these populations are often found in
pathologic conditions associated with infec-
tion, autoimmunity, and lymphomas
[28,31]. The aberrant expression of BLyS
and/or its receptors is often linked to B cell
autoimmunity and malignancies, favouring
the survival and emergence of self-reactive
cells at the TI stage [28,32,33]. Recently,
elevated expression of BLyS was found to
be associated with the expansion of TI and
MZ-likeB cells insalivary glands of patients
suffering from Sjo ¨gren’s syndrome [28]. A
similar phenomenon most likely occurs
during HIV infection, as supported by the
correlation between elevated blood levels of
auto-antibodies and high levels of BLyS
expression in the plasma and on the surface
ofbloodmonocytesofindividualswithHIV
[34,35]. Thus in the context of HIV disease
progression, there appears to be an early
commitment to produce ‘‘inflammatory’’
DCs expressing high levels of BLyS that are
recruited to the periphery, where they
contribute to B cell dysregulation. This
phenomenon seems to affect mainly imma-
ture and first line populations, allowing for
emergence of a disturbed and self-reactive
repertoire that can lead to autoimmune
manifestations and malignancies.However,
whether this process is regulated by the
host response and/or modulated by direct
and indirect viral effects remains to be
established.
Control of HIV Disease Is
Associated with Unaltered DC
Status and Preservation of the B
Cell Compartment
In contrast to observations in rapid and
classic HIV progressors, blood mDCs and
BLyS levels remained unaltered in avire-
mic slow progressors or ‘‘elite controllers’’
[2,22]. However, monocytic DC-precur-
sors of a CD11c
+CD14
+CD16
+ pheno-
type, which murine analogs settle periph-
eral organs in steady state conditions [24],
were found to be significantly increased
in the blood of elite controllers [22],
suggesting high turnover in the absence
of inflammation. Although the percentage
of circulating activated mature B cells and
precursor/activated MZ-like B cells re-
mained unaltered in elite controllers, the
proportion representing a population with
features of unactivated ‘‘mature MZ’’ B
cells was lower in these individuals when
compared to both classic and rapid HIV
progressors as well as healthy donors [2].
Although this may reflect early stages of
malfunction, we rather favour the view
that the capacity to recruit this population
to peripheral sites may be beneficial to the
‘‘control’’ of disease progression.
Given that mucosal DC populations are
gatekeepers of peripheral integrity and
amongst the first to be involved in the battle
against HIV, it is likely that they influence the
outcome of mucosal B cell responses towards
the virus [8,31,36]. Mucosal HIV-specific
IgA are abundant in highly exposed persis-
tently seronegative (HEPS) individuals [37],
but rather low in the context of HIV disease
progression [1]. Although the issue of
‘‘protection’’ conferred by mucosal HIV-
specific IgA remains controversial [37], in
many studies these antibodies have been
found to neutralize infection and inhibit viral
transcytosis in vitro. Furthermore, HIV-gp41
specific mucosal IgA produced by cervical B
cells from HEPS individuals presented signs
of hypermutation and affinity maturation
[38]. Together, these observations based on
natural control/immunity versus HIV sug-
gest that efforts to develop an effective
vaccine should consider soliciting HIV-spe-
cific mucosal IgA production. In support of
this, mucosal IgA and IgG, elicited through
mucosal vaccination with HIV-1 gp41 sub-
unit virosomes in nonhuman primates,
prevented systemic invasion following vaginal
simian-HIV challenge by blocking transcy-
tosis and by mediating antibody-dependent
cellular cytotoxicity (ADCC) [39]. Thus,
‘‘control’’ of HIV disease progression is
associated with normal mDC BLyS expres-
sion, likely contributing to ‘‘preservation’’ of
the B cell compartment and to its capacity
of generating both T-dependent and
-independent effective B cell responses, such
as mucosal IgA, viewed to block systemic
invasion by the virus (Figure 1).
Does DC Status Modulate the
Outcome of CD4
+ T Cell
Effector/Target Availability for
HIV?
DCs are involved in maintaining a
balance between tolerance and protective
Figure 1. The capacity to control immune homeostasis at mucosal sites, where the
main battle against HIV takes place, is reflected by a normal ‘‘non-inflammatory’’
BLyS/BAFF expression status. This is likely modulated through efficient epithelial cell:DC cross
talk, subsequently allowing for the generation of highly protective HIV-specific B and T cell
responses. In contrast, establishment of an imbalance at the level of mucosal immune
homeostasis will allow the excess ‘‘inflammatory’’ BLyS/BAFF expression status to lead to
dysregulated B and T cell responses, impairing the generation of highly protective HIV-specific
immunity. (Graphic art: Christian Charbonneau.)
doi:10.1371/journal.ppat.1002154.g001
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mucosal sites, where the main battle
with HIV takes place and immune ho-
meostasis warrants peripheral integrity.
Recent studies have demonstrated that
the homeostatic balance of regulatory
versus inflammatory responses at the
mucosal level involves cross talk between
epithelial cells and DCs [40–42]. Impor-
tantly, such mucosal immune homeostatic
processes are thought to operate mainly
through transforming growth factor
(TGF)-b and retinoic acid (RA)-dependent
mechanisms [40], modulating T regulato-
ry/effector ratios as well as IgA production
[31,36]. Interestingly, TLR-mediated epi-
thelial cell:DC cross talk at the level of
human tonsillar crypts was shown to
orchestrate B cell CSR through modula-
tion of BLyS levels via thymic stromal
lymphopoietin (TSLP) or secretory leuko-
cyte protease inhibitor (SLPI) [41]. As
depicted in Figure 1, the incapacity to
keep a balance in homeostatic processes,
which is likely to occur in individuals who
progress with HIV infection, will promote
inflammation and lead to disease perpet-
uation and excessive generation of T
effectors, prime targets for HIV [43]. In
contrast, the capacity to maintain immune
homeostasis at mucosal sites may allow for
better control of HIV infection. This view
is consistent with a report showing that
early prevention of macrophage inhibitory
protein (MIP)-3a (CCL20) production in
the genital tract of SIV-susceptible female
macaques prevented excessive recruitment
of DC populations, establishment of an
inflammatory milieu, and infection, de-
spite repeated intra-vaginal exposure to
high doses of SIV [44]. Furthermore,
studies of SIV infection in non-pathogenic
animal models have shown that their
control of disease progression appears
linked to better management of the
aberrant immune activation by early onset
of anti-inflammatory IL-10 production
and T regulatory activity. Moreover, fewer
Th17 effector target cells were generated
in non-pathogenic than in pathogenic SIV
infections [43], a process linked to a low
type I interferon (IFN)-gene profile and
low TLR7-signalling [45]. Interestingly,
both type I IFN- and TLR7-signalling are
involved in the regulation of BLyS expres-
sion patterns by DCs [20,46]. The fact
that low concentrations of BLyS were
shown to induce IL-10-producing murine
splenic MZ ‘‘regulatory’’ B cells, whereas
elevated BLyS concentrations promoted
MZ B cell activation, suggests that BLyS
may play an important role in modulating
the outcome of T regulatory/effector
balance via B cells [47].
Indeed, there is an increasing body of
experimental evidence demonstrating the
role of B cells in regulating the develop-
ment, proliferation, and maintenance of
CD4
+ T cell populations, through both
contact and/or cytokine mediated effec-
tor/regulatory functions [48,49]. Sporadic
depletion of B cells is an effective therapy
for several T cell–mediated autoimmune
diseases, allowing for a decline in inflam-
mation and favouring the emergence of
regulatory populations [48]. Decreased
effector and increased regulatory CD4
+
T cell functions were observed following
blocking of BLyS in type I-diabetic
(NOD) mice [50]. In a collagen-induced
model of rheumatoid arthritis, BLyS over
expression was shown to promote the
expansion of Th17 cells, and BLyS gene
silencing inhibited DC-mediated Th17 cell
differentiation in vitro [51]. These obser-
vations suggest that DCs may influence T
cell differentiation in a BLyS-mediated
manner either directly and/or indirectly
via modulation of B cell regulatory/
effector functions.
The overall outcome of HIV disease
may depend on the host’s capacity to
maintain dendritic cell (DC) homeostasis
at mucosalsites, where DC populations,
one of the earliest cell types to be exposed
to the virus, present an inherent capacity
to modulate the balance between toler-
ance and protection. DCs may influence
mucosal B cell responses against HIV
through contact and/or production of B
cell growth factors such as B lymphocyte
stimulator (BLyS/BAFF), which in turn
modulate the outcome of CD4
+ T cell
HIV effectors/targets. Recent observa-
tions of HIV/SIV infections in non-
pathogenic animal models and from
mucosal vaccination of nonhuman prima-
tes suggest that maintenance of systemic
integrity may be achieved through con-
straining highly efficient immune respons-
es to mucosal sites.
Concluding Remarks
BLyS expression levels correlate with
both the extent to which the B cell
compartment is compromised and HIV
disease progression status. The fact that
HIV elite controllers expressed relatively
low levels of BLyS suggest that therapeutic
blockage of BLyS in HIV progressors may
restore balanced effector to regulatory cell
ratios to reduce both HIV target cells and
systemic immune activation that are the
hallmarks of HIV disease progression.
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